USA and Japan — Protein Sciences Corporation and UMN Pharma Inc. announced today that Protein Sciences and UNIGEN Inc., a joint venture of UMN and IHI Corporation, entered into an agreement to source bulk Flublok influenza vaccine from Japan for the U.S. market.  The drug substances will be manufactured at the Gifu (Japan) Plant of UNIGEN.  UNIGEN manufactures Flublok for the Japan market in two 21,000L bioreactors – ten times the scale the vaccine is manufactured in the United States.  With this added capacity, Protein Sciences could provide as many as 25 million additional doses of Flublok each year to the U.S. flu vaccine supply.